In a major victory for its rare disease portfolio, Amgen (NASDAQ: AMGN) announced positive topline results on April 6, 2026, from its pivotal Phase 3 clinical trial evaluating a subcutaneous (SC) formulation of TEPEZZA (teprotumumab-trbw). The study, which utilized a convenient on-body injector, demonstrated efficacy that mirrors the high bar set by the original intravenous (IV) version, potentially revolutionizing the treatment landscape for patients suffering from moderate-to-severe active Thyroid Eye Disease (TED).

The immediate implications are profound: by transitioning from a time-consuming 60-to-90-minute clinic-based infusion to a bi-weekly subcutaneous injection that could eventually be administered at home, Amgen is addressing the primary barrier to TEPEZZA adoption. This clinical success not only bolsters Amgen’s multi-billion-dollar franchise against emerging generic and branded threats but also signals a meaningful commercial inflection point as the company targets "infusion-naive" patients who previously avoided treatment due to the logistical burdens of the IV regimen.

Clinical Breakthrough: The Move to On-Body Injection

The Phase 3 randomized, double-masked, placebo-controlled trial focused on the efficacy and safety of TEPEZZA delivered via an innovative on-body injector (OBI). The data revealed that 77% of patients treated with the subcutaneous formulation achieved a proptosis response—defined as a reduction in eye bulging of 2 mm or more—at week 24. This stands in stark contrast to the 19.6% response rate observed in the placebo group. Furthermore, patients in the treatment arm saw an average proptosis reduction of 3.17 mm, a statistically significant result that validates the SC formulation's ability to match the clinical potency of its IV predecessor.

The safety profile of the SC formulation remained consistent with the well-documented profile of IV TEPEZZA, with common adverse events including muscle spasms, nausea, and alopecia. Crucially, the injection site reactions were reported as mild-to-moderate and did not lead to any treatment discontinuations, suggesting high patient tolerability for the on-body device. This trial represents the culmination of a multi-year effort by Amgen to modernize the delivery of teprotumumab following its $27.8 billion acquisition of Horizon Therapeutics in 2023.

Market Reaction: Winners and Losers in the TED Space

Amgen (NASDAQ: AMGN) stands as the clear winner of this clinical update. Following the announcement, the company’s stock maintained its strong momentum, trading in the $340–$350 range, as analysts grew more confident in the company’s ability to defend its TED market share. By offering a more convenient administration route, Amgen is positioned to capture a larger share of the "active" TED population and potentially expand into chronic cases where the burden of IV therapy was deemed too high for the perceived benefit.

Conversely, the data has cast a shadow over Viridian Therapeutics (NASDAQ: VRDN). Viridian has been developing its own subcutaneous candidate, elegrobart, which recently reported Phase 3 proptosis response rates in the 54% to 63% range. With Amgen delivering a superior 77% response rate, investors have begun to pivot away from Viridian, fearing that its candidate may struggle to compete on efficacy, even if it reaches the market. The gap in clinical performance suggests that Amgen’s "IV-level efficacy in an SC bottle" will be difficult for challengers to overcome.

A Wider Shift Toward Patient-Centric Biologics

The success of subcutaneous TEPEZZA fits into a broader pharmaceutical industry trend where "treatment convenience" is becoming a primary battleground for drug manufacturers. As many blockbuster biologics face the "patent cliff," companies are increasingly utilizing subcutaneous delivery and proprietary devices to extend their intellectual property moats and improve patient adherence. Amgen’s use of an on-body injector is a prime example of this strategy, prioritizing the patient experience to maintain a competitive edge.

From a regulatory standpoint, the path for SC TEPEZZA appears straightforward. Having already proven the efficacy of the molecule in its IV form, Amgen is expected to file a supplemental Biologics License Application (sBLA) imminently. This move mirrors successful transitions seen in other therapeutic areas, such as the shift from IV to SC formulations in the oncology and immunology sectors. The FDA’s increasing familiarity with wearable injectors suggests that the approval process could be streamlined, potentially allowing for a commercial launch by late 2026 or early 2027.

The Road Ahead: Commercial Inflection and Competitive Pressures

In the short term, Amgen will focus on finalizing its regulatory submissions and preparing its sales force for a dual-offering strategy. The company must navigate the transition carefully to ensure that patients currently on IV therapy have a clear pathway to the SC version if they choose. In the long term, the commercial success of the SC formulation will be a critical driver of Amgen’s rare disease revenue, helping to offset the expected erosion of older blockbusters like Prolia and Xgeva, which are facing the imminent arrival of biosimilars.

Strategic challenges remain, however. While the SC data is strong, Amgen must also maintain focus on its high-profile obesity candidate, MariTide. Investors are currently weighing Amgen’s traditional strengths in rare diseases and bone health against its potential in the hyper-competitive metabolic market. The ability of the management team to execute on multiple fronts—securing the TEPEZZA franchise while breaking into the weight-loss sector—will determine if the stock can reach the optimistic analyst price targets of $400 and beyond.

Summary and Investor Outlook

Amgen’s positive Phase 3 topline data for subcutaneous TEPEZZA marks a pivotal moment for the thyroid eye disease market. By delivering 77% efficacy through a convenient on-body injector, the company has effectively raised the bar for all current and future competitors. This development not only provides a lifeline for the TEPEZZA franchise in the face of rising competition but also offers patients a significantly less burdensome treatment option.

Moving forward, investors should keep a close watch on the timing of the sBLA filing and the subsequent FDA decision. Additionally, the quarterly sales performance of the existing IV formulation will be a key indicator of whether the market is "holding its breath" for the SC version or if there is still room for growth in the current regimen. As of April 2026, Amgen has reinforced its reputation as a leader in biologic innovation, turning a potential competitive threat into a clear path for commercial expansion.

This content is intended for informational purposes only and is not financial advice